Galectin Therapeutics, Inc. announced results from its NAVIGATE trial, which evaluated belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal ...

Galectin Therapeutics (NASDAQ:GALT) lost ~25% in the premarket on Friday after its NAVIGATE clinical trial for lead candidate belapectin failed to reach the main goal in patients with liver ...

Galectin Therapeutics (GALT) announced results from its global clinical trial NAVIGATE evaluating belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis cirrhosis and portal ...

Galectin Therapeutics, Inc. announced that it will present top-line results from the NAVIGATE trial regarding its drug belapectin for patients with MASH cirrhosis and portal hypertension at the ...

Galectin's said it hoped that the therapy, called belapectin, would prevent varices, which are abnormally dilated blood vessels. While varices occurred 43% less when patients took belapectin ...

Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases ...

H.C. Wainwright analyst Ed Arce downgraded Galectin Therapeutics (GALT) to Neutral from Buy with no price target after the company’s Phase 2b NAVIGATE trial of belapectin in patients with ...

Galectin's lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it ...